JP2013513588A5 - - Google Patents

Download PDF

Info

Publication number
JP2013513588A5
JP2013513588A5 JP2012542580A JP2012542580A JP2013513588A5 JP 2013513588 A5 JP2013513588 A5 JP 2013513588A5 JP 2012542580 A JP2012542580 A JP 2012542580A JP 2012542580 A JP2012542580 A JP 2012542580A JP 2013513588 A5 JP2013513588 A5 JP 2013513588A5
Authority
JP
Japan
Prior art keywords
disease
group
parkinson
compound
stroke
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012542580A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013513588A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2010/069535 external-priority patent/WO2011070177A2/en
Publication of JP2013513588A publication Critical patent/JP2013513588A/ja
Publication of JP2013513588A5 publication Critical patent/JP2013513588A5/ja
Pending legal-status Critical Current

Links

JP2012542580A 2009-12-11 2010-12-13 Ｇｄｎｆファミリーリガンド（ｇｆｌ）のミメティックまたはｒｅｔシグナル経路活性化因子を用いた、神経系細胞の生存を容易にするための方法 Pending JP2013513588A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28585809P 2009-12-11 2009-12-11
US61/285,858 2009-12-11
PCT/EP2010/069535 WO2011070177A2 (en) 2009-12-11 2010-12-13 Methods of facilitating neural cell survival using gdnf family ligand (gfl) mimetics or ret signaling pathway activators

Publications (2)

Publication Number Publication Date
JP2013513588A JP2013513588A (ja) 2013-04-22
JP2013513588A5 true JP2013513588A5 (OSRAM) 2014-02-06

Family

ID=43502911

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012542580A Pending JP2013513588A (ja) 2009-12-11 2010-12-13 Ｇｄｎｆファミリーリガンド（ｇｆｌ）のミメティックまたはｒｅｔシグナル経路活性化因子を用いた、神経系細胞の生存を容易にするための方法

Country Status (9)

Country Link
US (1) US8901129B2 (OSRAM)
EP (1) EP2509953B1 (OSRAM)
JP (1) JP2013513588A (OSRAM)
CN (2) CN103180297A (OSRAM)
AU (1) AU2010329847A1 (OSRAM)
BR (1) BR112012014022A2 (OSRAM)
CA (1) CA2783934A1 (OSRAM)
MX (1) MX2012006580A (OSRAM)
WO (1) WO2011070177A2 (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014041179A1 (en) * 2012-09-17 2014-03-20 Chemedest Ltd. Treatment of peripheral neuropathy using gfr(alpha)3 type receptor agonists
CN103146798B (zh) * 2013-02-25 2015-04-08 潍坊易思特生物科技有限公司 一种测定重组人胶质细胞源性神经营养因子活性的细胞学方法
CN105640955B (zh) * 2016-01-28 2019-12-24 昆明医科大学 一种Aminoquinol的新用途
CN105906608B (zh) * 2016-05-03 2018-10-19 中山大学 8-氨基喹啉-松果体素杂联体及其药物组合物
BR112018073300A2 (pt) 2016-05-13 2019-03-26 Instituto De Medicina Molecular métodos para tratamento de doenças associadas com as células ilc3
BR112019012709A2 (pt) * 2016-12-21 2019-11-26 AlzeCure Pharma AB composto, método para tratar e/ou prevenir uma doença distinguida por sinalização deficiente de neurotrofinas e/ou outros fatores tróficos, uso de um composto, composição farmacêutica, produto de combinação, kit de peças, e, processos para preparação de um composto e de uma composição farmacêutica.
CN107337641B (zh) * 2017-07-01 2020-04-28 广东医科大学 一种4-柔性胺基-2-芳乙烯基喹啉类衍生物及其制备方法和应用
EP4314071A1 (en) 2021-03-31 2024-02-07 Cambridge Enterprise Limited Therapeutic inhibitors of gdf15 signalling
WO2022254255A1 (en) 2021-06-03 2022-12-08 Fundacao D. Anna De Sommerchampalimaud E Dr. Neuro-mesenchyme units control ilc2 and obesity via a brain-adipose circuit
AU2022387671B2 (en) 2021-11-12 2024-11-07 Axent Biosciences Inc. Methods for production of functional neurons
CA3262970A1 (en) 2022-07-28 2024-02-01 Genecode NEW SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORAGE AGENTS
AU2023313331A1 (en) * 2022-07-28 2025-01-30 Genecode [4-[5-(methylsulfonyl)-phenyl]piperazin-1-yl]-(phenyl)methanone derivatives and similar compounds with gfr alpha 1-ret activity as neuroprotective agents for the treatment of neurological disorders
EP4602030A1 (en) 2022-10-14 2025-08-20 Genecode Novel piperazine-based sulfonamides and their use as neuroprotective and/or neurorestorative agents

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2531011A (en) 1949-01-22 1950-11-21 Sterling Drug Inc 3-chloro-9-[2-(2-hydroxyethylamino)-ethylamino] acridine and method for its production
US3232945A (en) * 1962-08-13 1966-02-01 S E Massengill Company 7,8,9,10-tetrahalo-6h-cyclohepta-(b)-quinolines
US3458525A (en) 1966-07-01 1969-07-29 American Home Prod Spiro(indoline-3,2'-thiazolidine)-2-one and derivatives
US4426330A (en) 1981-07-20 1984-01-17 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4534899A (en) 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
DK569087A (da) * 1986-10-31 1988-05-01 Sumitomo Pharma Quinolin-derivater, deres fremstilling og anvendelse
WO1988007851A1 (en) 1987-04-06 1988-10-20 Innovative Therapeutics Corporation Liposome entrapped n-methyl-d-aspartate receptor blockers
WO1988007852A1 (en) 1987-04-06 1988-10-20 Innovative Therapeutics Corporation Liposome entrapped magnesium
US4939174A (en) 1988-02-26 1990-07-03 Shashoua Victor E Appetite suppression with dopamine-fatty acid conjugates
US4933324A (en) 1988-02-26 1990-06-12 Shashoua Victor E Fatty acid-neuroactive drug conjugate as a prodrug
US5284876A (en) 1988-02-26 1994-02-08 Neuromedica, Inc. Method of treating tardive dyskinesia using dopaminergic agents of prodrugs of therapeutic agents
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5019400A (en) 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US5227170A (en) 1989-06-22 1993-07-13 Vestar, Inc. Encapsulation process
US4999430A (en) * 1989-07-31 1991-03-12 Warner-Lambert Company Derivatives of 1,2,3,4-tetrahydro-9-acrisinamine
US5182107A (en) 1989-09-07 1993-01-26 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US5672683A (en) 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
US5154924A (en) 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
CA2025907A1 (en) 1989-09-21 1991-03-22 Franklin D. Collins Method of transporting compositions across the blood brain barrier
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5356633A (en) 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
US5527528A (en) 1989-10-20 1996-06-18 Sequus Pharmaceuticals, Inc. Solid-tumor treatment method
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
CA2029497C (en) * 1989-11-08 2002-06-04 Kunihiro Ninomiya (Deceased) 4-acylaminopyridine derivative
JPH03236315A (ja) 1989-12-05 1991-10-22 Nippon Oil & Fats Co Ltd 抗精神病薬
US5469854A (en) 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5109921A (en) 1991-04-29 1992-05-05 Halliburton Company Controlled weak point for wireline cable
JP3220180B2 (ja) 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム
US5521291A (en) 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5260308A (en) 1991-11-06 1993-11-09 Mayo Foundation For Medical Education And Research Method to increase permeability of the blood-nerve/brain barriers to proteins
JPH07509444A (ja) 1991-11-26 1995-10-19 アルカーメス・インコーポレーテツド トランスフェリンセレプター特異的抗体−神経薬又は診断薬複合体の製造法
CA2129514A1 (en) 1992-03-12 1993-09-16 M. Amin Khan Controlled released acth containing microspheres
DE69328430T2 (de) 1992-07-27 2001-01-25 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Zielgerichte liposome zur blut-hirne schranke
US5583020A (en) 1992-11-24 1996-12-10 Ribozyme Pharmaceuticals, Inc. Permeability enhancers for negatively charged polynucleotides
JP3351476B2 (ja) 1993-01-22 2002-11-25 三菱化学株式会社 リン脂質誘導体及びそれを含有するリポソーム
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US5462854A (en) 1993-04-19 1995-10-31 Beckman Instruments, Inc. Inverse linkage oligonucleotides for chemical and enzymatic processes
US5534259A (en) 1993-07-08 1996-07-09 Liposome Technology, Inc. Polymer compound and coated particle composition
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5417978A (en) 1993-07-29 1995-05-23 Board Of Regents, The University Of Texas System Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5591721A (en) 1994-10-25 1997-01-07 Hybridon, Inc. Method of down-regulating gene expression
US5512295A (en) 1994-11-10 1996-04-30 The Board Of Trustees Of The Leland Stanford Junior University Synthetic liposomes for enhanced uptake and delivery
JP2002510319A (ja) 1997-07-01 2002-04-02 アイシス・ファーマシューティカルス・インコーポレーテッド オリゴヌクレオチドの消化管を介したデリバリーのための組成物及び方法
US6235769B1 (en) 1997-07-03 2001-05-22 Sugen, Inc. Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase
JP2002537343A (ja) 1999-02-23 2002-11-05 アイシス・ファーマシューティカルス・インコーポレーテッド 多重粒子製剤
US6287860B1 (en) 2000-01-20 2001-09-11 Isis Pharmaceuticals, Inc. Antisense inhibition of MEKK2 expression
FI20000480A0 (fi) * 2000-03-01 2000-03-01 Orion Yhtymae Oyj Kinoliini- ja naftaleenijohdannaisia alfa-2 antagonisteina
EP1339702A1 (en) * 2000-03-15 2003-09-03 Warner-Lambert Company 5-amide substituted diarylamines as mek inhibitors
EP1581167A4 (en) 2002-07-09 2008-10-29 Alpha Res Group Llc COMPOSITIONS AND METHODS FOR TREATING PARKINSON AND TARDIVER DYSKINESIA
US20040034019A1 (en) * 2002-08-08 2004-02-19 Ronald Tomlinson Piperazine and piperidine derivatives
AU2003263518A1 (en) 2002-10-09 2004-05-04 Pfizer Products Inc. Pyrazole compounds for treatment of neurodegenerative disorders
EP1667983A4 (en) * 2003-09-23 2010-07-21 Merck Sharp & Dohme PYRAZOL MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
CN101198598A (zh) * 2004-05-20 2008-06-11 弗尔德里克斯制药股份有限公司 2-((杂)芳基)-苯并噁唑化合物及其衍生物、组合物以及用于稳定和抑制甲状腺素转运蛋白错重叠的方法
EP1856099A2 (en) 2005-03-03 2007-11-21 Sirtris Pharmaceuticals, Inc. Acridine and quinoline derivatives as sirtuin modulators
GB0505086D0 (en) 2005-03-11 2005-04-20 Glaxo Group Ltd Compounds
EP1904491A2 (en) * 2005-05-31 2008-04-02 Vertex Pharmaceuticals Incorporated Heterocycles useful as modulators of ion channels
DE202005008426U1 (de) 2005-05-31 2005-09-15 Ricon Sieb Und Foerdertechnik Fördervorrichtung mit Fördertuch
EP2526942B1 (en) 2005-06-08 2017-08-09 The University of North Carolina At Chapel Hill Methods of facilitating neural cell survival using non-peptide and peptide BDNF neurotrophin mimetics
WO2008010984A2 (en) * 2006-07-17 2008-01-24 The Trustees Of The University Of Pennsylvania Acridine activation of p53 and uses thereof
US7605265B2 (en) 2007-01-22 2009-10-20 Biotechnology Research Corporation Ltd. Heterodimers and methods of using them
US20080234267A1 (en) * 2007-03-20 2008-09-25 Karen Elizabeth Lackey Compounds and Methods of Treatment
WO2009024611A2 (en) 2007-08-22 2009-02-26 Abbott Gmbh & Co. Kg 4-benzylaminoquinolines, pharmaceutical compositions containing them and their use
US7863295B2 (en) * 2008-02-12 2011-01-04 Children's Medical Center Corporation Treatments for neuropathy
WO2009148659A2 (en) 2008-03-05 2009-12-10 Georgetown University Antimalarial quinolines and methods of use thereof
US10867398B2 (en) 2017-11-21 2020-12-15 Reliance Core Consulting LLC Methods, systems, apparatuses and devices for facilitating motion analysis in an environment

Similar Documents

Publication Publication Date Title
JP2013513588A5 (OSRAM)
JP2013545730A5 (OSRAM)
JP2012530779A5 (OSRAM)
JP2016514100A5 (OSRAM)
JP2009504763A5 (OSRAM)
JP2010514832A5 (OSRAM)
SI3018132T1 (en) Condensed imidazole derivatives useful as IDO inhibitors
CN101534904A (zh) 治疗血小板过量的bcl抑制剂
MX344308B (es) Derivados de quinolina carboxamida y quinolina carbonitrilo como moduladores alostericos negativos de mglur2, composiciones y su uso.
RU2013155586A (ru) [1,3]оксазины
JP2013006854A5 (OSRAM)
EP3404029A3 (en) Pyrimido-pyridazinone compounds and methods and use thereof
RU2010119458A (ru) 1,3,5-тризамещенное производное триазола
EA201500050A1 (ru) Бифтордиоксалан-амино-бензимидазольные ингибиторы киназы для лечения рака, аутоиммунного воспаления и нарушений цнс
JP2015508092A5 (OSRAM)
RU2013150861A (ru) Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
JP2012523395A5 (OSRAM)
RU2016131875A (ru) Производные n-фениллактама, способные стимулировать нейрогенез, и их применение при лечении заболеваний нервной системы
RU2013113634A (ru) Агонисты рецепторов нейротрофинов и их применение в качестве лекарственных средств
RU2013130878A (ru) Гидроксилированные производные аминотриазола в качестве агонистов рецептора alx
MY183111A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
JP2017509676A5 (OSRAM)
PH12015500398A1 (en) Ethynyl derivatives as modulators of mglur5 receptor activity
WO2019025588A1 (en) METHODS OF TREATING ALTERATIONS IN BEHAVIOR
RU2013147917A (ru) Новые модуляторы кортикальной дофаминергической и опосредованной nmda-рецептором глутаматергической нейротрансмиссии